Australija - engleski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - naloxone hydrochloride dihydrate, quantity: 400 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; dilute hydrochloric acid - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval for listing of these goods as pharmaceutical benefits were approved as specified in the letter of 29 october 1992 from dr alex proudfoot. indications: for the complete or partial reversal of narcotic depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone and the narcotic-antagonist analgesics such as nalbuphine, methadone and butorphanol. indications as at 8 january 2004: naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

a-s medication solutions - prazosin hydrochloride (unii: x0z7454b90) (prazosin - unii:xm03yj541d) - prazosin hydrochloride capsules usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes

Australija - engleski - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram (equivalent: naloxone hydrochloride?, qty 400 microgram) - injection - excipient ingredients: sodium chloride; water for injections; edetate sodium; hydrochloric acid - naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dextropropoxyphene hydrochloride 32.5mg; paracetamol 325mg - capsule - 325mg/32.5mg - active: dextropropoxyphene hydrochloride 32.5mg paracetamol 325mg excipient: carmellose sodium colloidal silicon dioxide gelatin magnesium stearate

Australija - engleski - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dextropropoxyphene hydrochloride; paracetamol -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

dextropropoxyphene hydrochloride; paracetamol -

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology, adjunctive use in septic shock ). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients contained in the formulation. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known to occur. caution: certain glass syringes may malfunction, break or clog when connected to some needleless luer access devices (nlads) and needles. this syringe has a larger internal syringe tip and an external collar (luer collar). the external collar must remain attached to the syringe. data show that the syringe achieves acceptable connections with the bd eclipse™ needle and the terumo surguard3™ safety needle and with the following non-center post nlads: bd smartsite™ and bd-q syte™. the data also show acceptable connections are achieved to the center post icu medical clave™. however, spontaneous disconnection of this glass syringe from needles and nlads with leakage of drug product may occur. assure that the needle or nlad is securely attached before beginning the injection. visually inspect the glass syringe-needle or glass syringe-nlad connection before and during drug administration. figure 1 1. inspect the outer packaging (plastic tube) by verifying: - plastic tube integrity - drug name - drug strength - dose volume - route of administration - expiration date to be sure that the drug has not expired - sterile field applicability do not use if package has been damaged. 2. remove the plastic tube cap of the outer packaging to access the syringe. 3. remove the syringe from the plastic tube. 4. perform visual inspection on the syringe by verifying: - absence of syringe damage - absence of external particles - absence of internal particles - proper drug color - expiration date to be sure that the drug has not expired - drug name - drug strength - dose volume - route of administration - sterile field applicability 5. push plunger rod slightly to break the stopper loose while tip cap is still on. 6. remove tip cap by twisting it off. (see figure 2) figure 2         7. discard the tip cap. 8. expel air bubble. 9. adjust dose by expelling extra volume (where applicable) from the syringe into sterile material prior to administration. 10. connect the syringe to appropriate injection connection depending on route of administration. before injection, ensure that the syringe is securely attached to the needle or needleless luer access device (nlad). 11. depress plunger rod to deliver medication. ensure that pressure is maintained on the plunger rod during the entire administration. 12. remove syringe from nlad (if applicable) and discard into appropriate receptacle. to prevent needle-stick injuries, needles should not be recapped. notes: - all steps must be done sequentially - do not autoclave syringe - do not use this product on a sterile field - do not introduce any other fluid into the syringe at any time - this product is for single dose only; discard unused portion. manufactured by: hikma pharmaceuticals usa inc. berkeley heights, nj 07922 462-892-01 revised may 2023

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

general injectables & vaccines, inc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology: adjunctive use in septic shock). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or any of the other ingredients contained in the formulation. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

medical purchasing solutions, llc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection, usp is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology, adjunctive use in septic shock). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients contained in the formulation. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known to o

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hf acquisition co. llc, dba healthfirst - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see indications & usage: adjunctive use in septic shock). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or any of the other ingredients contained in the formulation. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known